Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study

Allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with acute myelogenous leukemia (AML) with high cytogenetic or molecular risk. It is also the treatment of choice for patients with AML who fail to respond to conventional chemotherapy or who present with early disease relapse. It is also a therapeutic choice for patients with chronic myelogenous leukemia in the blast phase (CML-BP) who are refractory to second-generation tyrosine kinase inhibitors (TKIs). The intensity of the preparative regimen is usually tailored to the perceived capacity of the recipient to tolerate dose-intensive conditioning.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research